Exacerbations and lung function decline in COPD: New insights in current and ex-smokers

Respiratory Medicine

Volumn 101, Issue 6, 2007, Pages 1305-1312

  Makris, D ^a   Moschandreas, J ^a   Damianaki, A ^b   Ntaoukakis, E ^b   Siafakas, N M ^a   Milic Emili, J ^c   Tzanakis, N ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b Agios Georgios General Hospital of Chania   (Greece)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Dyspnoea; Forced expiratory volume in 1 s; Smoking

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; SALBUTAMOL;

ADULT; AGED; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SMOKING; SMOKING CESSATION; SPIROMETRY; STATISTICAL SIGNIFICANCE;

AGED; CHRONIC DISEASE; COUGH; DISEASE PROGRESSION; DYSPNEA; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SMOKING; SMOKING CESSATION; SPIROMETRY;

EID: 34247639520     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.10.012     Document Type: Article

References (33)

1. White A.J., Gompertz S., and Stockley R.A. Chronic obstructive pulmonary disease. 6: The aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 58 1 (2003) 73-80
2. Miravitlles M., Murio C., and Guerrero T. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. Eur Respir J 17 5 (2001) 928-933
3. Seemungal T.A., Donaldson G.C., Bhowmik A., Jeffries D.J., and Wedzicha J.A. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161 5 (2000) 1608-1613
4. Fletcher C., and Peto R. The natural history of chronic airflow obstruction. Br Med J 1 (1977) 1645-1648
5. Howard P. A long-term follow-up of respiratory symptoms and ventilatory function in a group of working men. Br J Ind Med 27 (1970) 326-333
6. Decramer M., Gosselink R., Bartsch P., Lofdahl C.G., Vincken W., Dekhuijzen R., et al. Effect of treatments on the progression of COPD: report of a workshop held in Leuven. Thorax 60 4 (2005) 343-349
7. 1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 358-364
8. Donaldson G.C., Seemungal T.A., Bhowmik A., and Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57 10 (2002) 847-852
9. Pauwels R.A., Buist A.S., Calverley P.M., et al. GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163 5 (2001) 1256-1276
10. Tzanakis N., Anagnostopoulou U., Filaditaki V., et al. COPD group of the Hellenic Thoracic Society. Prevalence of COPD in Greece. Chest 125 3 (2004) 892-900
11. Martinez J.A., Straccia L., Sobrani E., Silva G.A., Vianna E.O., and Filho J.T. Dyspnea scales in the assessment of illiterate patients with chronic obstructive pulmonary disease. Am J Med Sci 320 (2000) 240-243
12. Ferris B.G. Epidemiology standardization project. II. Recommended respiratory disease questionnaires for use with adults and children in epidemiological research. Am Rev Respir Dis 118 (1978) 7-57
13. Middleton E.T., and Morice A.H. Breath carbon monoxide as an indication of smoking habit. Chest 117 3 (2000) 758-763
14. American Thoracic Society. (ATS). Standardization of spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med 152 (1995) 1107-1136
15. Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K., and Nelson N.A. Antibiotic therapy in exacerbation of chronic obstructive pulmonary disease. Ann Intern Med 106 (1987) 196-200
16. Tzanakis N., Kallergis K., Bouros D.E., et al. Short-term effects of wood smoke exposure on the respiratory system among charcoal production workers. Chest 119 4 (2001) 1260-1265
17. Sherrill D., and Viegi G. On modelling longitudinal pulmonary function data. Am J Respir Crit Care Med 154 (1996) S217-S222
18. Ihaka R., and Gentleman R.A. R: A language for data analysis and graphics. J Comput Graph Stat 3 (1996) 299-314
19. Siafakas N.M., Vermeire P., Pride N.B., et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 8 8 (1995) 1398-1420
20. Miravitlles M., Ferrer M., Pont A., Zalacain R., Alvarez-Sala J.L., Masa F., et al., IMPAC Study Group. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 59 5 (2004) 387-395
21. Seemungal T.A., Donaldson G.C., Paul E.A., Bestall J.C., Jeffries D.J., and Wedzicha J.A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157 (1998) 1418-1422
22. Gompertz S., Bayley D.L., Hill S.L., and Stockley R.A. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 56 1 (2001) 36-41
23. Patel I.S., Seemungal T.A., Wilks M., Lloyd-Owen S.J., Donaldson G.C., and Wedzicha J.A. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 57 9 (2002) 753-754
24. 1: results from the Lung Health Study. Eur Respir J 25 (2005) 1011-1017
25. Burge P.S., Calverley P.M., Jones P.W., Spencer S., Anderson J.A., and Maslen T.K. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 320 7245 (2000) 1297-1303
26. Lindberg A., Bjerg-Backlund A., Ronmark E., Larsson L.G., and Lundback B. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 100 2 (2006) 264-272
27. 1-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med 164 10 (2001) 1805-1809
28. 1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 153 5 (1996) 1530-1535
29. Rutgers S.R., Postma D.S., ten Hacken N.H., Kauffman H.F., van Der Mark T.W., Koeter G.H., et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 55 1 (2000) 12-18
30. Turato G., Di Stefano A., Maestrelli P., et al. Effect of smoking cessation on mononuclear cell infiltrationin the bronchial mucosa of subjects with chronic bronchitis. Eur Respir J 7 (1994) 247s
31. Hodge S., Hodge G., Holmes M., et al. Increased airway epithelial and Tcell apoptosis in COPD remains despite smoking cessation. Eur Respir J 25 3 (2005) 447-454
32. Shapiro S.D. End-stage chronic obstructive pulmonary disease: the cigarette is burned out but inflammation rages on. Am J Respir Crit Care Med 164 3 (2001) 339-340
33. Andersson F., Borg S., Jansson S.A., Jonsson A.C., Ericsson A., Prutz C., et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 96 9 (2002) 700-708